The Cambridge/London Corridor: Its Strength and Impact on the UK – Harriet Fear, One Nucleus

Jun 30, 2015

The UK has one of the strongest and most productive life sciences sectors in the world, generating turnover of over £50 billion. There are nearly 5000 companies in the wider health life science sector (including non-manufacturing and service companies) in the UK. £4.21 billion was spent on pharmaceutical R&D in the UK in 2012, 25% of the total industrial R&D spend and 34% of total manufacturing industry R&D. Harriet Fear, Chief Executive at One Nucleus, shares her thoughts on the Cambridge/London life science and healthcare corridor. ...

Read More

The Evolution of the Life Sciences Sector and the Role of Biotech Incubators –

Jun 30, 2015

The life science sector is growing in significance to the world economy, and in particular for London and the UK. A biotech incubator with a 15-year history, the London BioScience Innovation Centre is ideally placed to serve the changing needs of biotech companies and to identify future opportunities and developments in the life science sector. Lucy Garnsworthy, Communications Manager at the London BioScience Innovation Centre, deals with the evolution of the life sciences sector and she explains the role of biotech incubators. ...

Read More

Changing Healthcare Landscape and its Impact on the Pharmaceutical Industry – Sunil Shewale, Sameer Parekh, Serum Institute

Jun 30, 2015

The pharmaceutical industry is a success story providing employment and ensuring that essential drugs at affordable prices are available to the therapeutic naïve population. At the same time it is one of the most regulated industries globally. Until recently, pharma investments in R&D and innovation resulted in patent- protected, high-margin revenue streams. Within this white paper, Sunil Shewale and Sameer Parekh from Serum Institute focus on the pharmaceutical industry from a different point of view. ...

Read More

Prioritising Health Economics Responsibilities to Impact Payer Pricing and Formulary Decisions – Victoria Cavicchi, Cutting Edge Information

Jun 30, 2015

Throughout a product’s lifecycle, health economics and outcomes research (HEOR) teams take on a number of activities to support a company’s broader market access efforts. In addition to supporting brands nearing regulatory approval, HEOR groups must be able to support teams negotiating pricing and reimbursement. Victoria Cavicchi, Research Analyst at Cutting Edge Information, discusses prioritising health economics responsibilities to impact payer pricing and formulary decisions. ...

Read More

US Healthcare Prepares for ICD-10 Transition -Jeffrey Goldstein, Allscript

Jun 30, 2015

This year US healthcare organisations are preparing to move from 13,000 ICD-9 codes to 68,000 ICD-10 codes (and this does not include procedures). It is a monumental task requiring strategies that apply to any organisational change of this size. Within this white paper Jeffrey Goldstein, Clinical Transformation Consultant at Allscripts, shares his thoughts on how US healthcare prepares for ICD-10 transition. ...

Read More